Sanofi's amlitelimab demonstrated clinically meaningful efficacy in heterogeneous inflammatory asthma, showing over 70% reduction in exacerbations in patients with specific biomarkers at week 60 of the TIDE-Asthma phase 2 study.
Sanofi Healthcare has received approval from the CDSCO panel in India to conduct a Phase 2 clinical trial for SAR443765 (lunsekimig) in asthma patients.
Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
Johnson & Johnson will acquire Yellow Jersey Therapeutics for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.